

RESEARCH

BOB ECONOMICS RESEARCH | MONTHLY ECONOMIC BUFFET

Economic Round-up: Jul 2026

PERSISTENT SYSTEMS | TARGET: Rs 3,310 | -41% | SELL

1Q strong but has issues. Nagarro M&A too big a bite?

ESCORTS KUBOTA | TARGET: Rs 2,869 | -8% | SELL

Steady show; exports below par, no respite; retain SELL

AUTOMOBILES

Monsoon recovery not a dampener, July surprises positively

SUMMARY

INDIA ECONOMICS: MONTHLY ECONOMIC BUFFET

The West Asia conflict remained a focal point, keeping the global market on the edge. This was on the back of the exchange of military hostilities between the US and Iran, with attacks even spreading across the Gulf towards the Red Sea and the Mediterranean facility. However, recently there have been news reports that the strikes have been paused after 2 weeks and a peace deal has been proposed which is contingent on reopening of the Strait of Hormuz as well as bringing an end to Iran's nuclear programme as part of the deal.

[Click here](#) for the full report.

PERSISTENT SYSTEMS

- 1QFY27 revenue grows 4.1% QoQ CC, driven by Hitech vertical/Top 5 accounts. Working capital deteriorates - OCF/PAT at ~24%
- Medium term worry - how PSYS will digest oversized (~23x size of the previous largest M&A, in revenue) lower quality Nagarro
- M&A risks and ~34xPE keeps us cautious. We stick to conservative Target PE multiple of 16.9x and maintain SELL

[Click here](#) for the full report.



ESCORTS KUBOTA

- Steady growth in key markets North (22%) and Central (~15%) drives domestic volume up ~23% leading to ~36bps market share gain
- Gross margins compress ~358bps YoY due to cost inflation impacts of ~500bps; further ~1.5-2% cost impact expected in Q2FY27
- Retain FY27E/FY28E/FY29E EBITDA/EPS to factor growth offsetting cost Value at 20x P/E multiple; revise TP to Rs 2,869 (Rs 2,786). SELL

[Click here](#) for the full report.

AUTOMOBILES

- OEMs continue positive volume growth momentum despite monsoon, entry level spurt boost PVs (37%); Premium segment spurts 2W (29%)
- Infrastructure spending and freight activity levels remain healthy as utilization sustains driving CV growth (~33% YoY)
- Improving monsoon and faster Kharif sowing sustain rural demand, supporting tractor growth (~20% YoY); 3W growth persistent (31% YoY)

[Click here](#) for the full report.

MONTHLY ECONOMIC BUFFET

03 August 2026

Economic Round-up: Jul 2026

Jahnavi Prabhakar
Economist

The West Asia conflict remained a focal point, keeping the global market on the edge. This was on the back of the exchange of military hostilities between the US and Iran, with attacks even spreading across the Gulf towards the Red Sea and the Mediterranean facility. However, recently there have been news reports that the strikes have been paused after 2 weeks and a peace deal has been proposed which is contingent on reopening of the Strait of Hormuz as well as bringing an end to Iran's nuclear programme as part of the deal.

The talks currently are underway with Saudi Arabia and Oman's counterparts. As a result, crude price moderated, surrounded by optimism around the ongoing talks. On the macro front, major global central banks kept policy rates unchanged with a hawkish hold. On the domestic front, the focus would shift towards the RBI which is also expected to maintain the status quo. The recent news of Bloomberg deferring the inclusion of Indian bonds in the Global aggregate bond index could put some pressure on the rupee and even push yields higher, given the delay in inflows. On the positive side, RBI has reported that US\$ 40.8bn was mobilised through FCNR (B), OFCBs and ECBs route, till 31 Jul'26, out of which US\$ 36.7bn was mobilised through FCNR (B) deposits. This is expected to push inflows and support the rupee. On the rural front, the recent deluge has resulted in surplus rains in Jul'26 against a deficit noted in Jun'26. However, IMD has projected below normal rain in Aug'26 which needs to be tracked as moderate risks of El Nino persist.

Global central banks: Recent commentaries by monetary policymaker globally suggest that they will continue to track inflation risks amidst the ongoing tensions in the Middle East. Major Central Banks had decided to keep the policy rates on hold in their last meeting. However, there is a growing likelihood of tightening in the near term especially by US Fed and ECB. Given that the US Fed has recently delivered a hawkish hold with 3-dissenters voting for a rate hike. ECB continued with the hawkish rhetoric given the recent commentary by the ECB chief wherein she reiterated the upside risk to inflation and this was further supported by Eurozone inflation which ticked up in Jul'26 and thereby strengthened prospects of rate hike in Sep'25. On the domestic front, RBI is expected to maintain status quo and retain its stance in the upcoming policy meeting. Though, we see this could be the right opportunity for the central bank to prepare markets for a future hike. Growth and inflation forecasts will also be left unchanged. Members will also remain watchful regarding inflation, given volatility in international oil prices and weak monsoon. A clear picture on sowing will also be available by Sep'26.



SELL

TP: Rs 3,310 | ▼ 41%

PERSISTENT SYSTEMS

| IT Services

| 04 August 2026

1Q strong but has issues. Nagarro M&A too big a bite?

- 1QFY27 revenue grows 4.1% QoQ CC, driven by Hitech vertical/Top 5 accounts. Working capital deteriorates - OCF/PAT at ~24%
- Medium term worry - how PSYS will digest oversized (~23x size of the previous largest M&A, in revenue) lower quality Nagarro
- M&A risks and ~34xPE keeps us cautious. We stick to conservative Target PE multiple of 16.9x and maintain SELL

Girish Pai
Research Analyst
Lopa Notaria, CFA
Research Associate
research@bobcaps.in

Revenue ahead of expectation but has issues: PSYS saw revenue growth of 4.1% QoQ CC, ahead of our estimate of 3.0%. Growth QoQ was narrow (Hitech and top 5 clients drove incremental growth) and was working capital intensive (OCF/PAT - ~24%). One of the key issues we see across various firms reporting 1QFY27 results has been deterioration in working capital (likely due to clients' capital commitments to AI). Total TCV at US\$1.15bn (up 91% QoQ and 120% YoY) was the highest ever, driven by US\$650mn large deal with a software player.

Organic growth will have to be increasingly driven by large deals. At its current size we believe the deals which will move the revenue needle will be ones that are in the ACV range of US\$100-200mn. These in our view will have to be deals won against competition from Tier-1 players and which will likely require substantial productivity pass back and may be margin dilutive to some extent during the contract lives. The US\$650mn won from a software player seems to be an internal spend on possibly a bunch of mature products that has been moved out along with the respective teams.

Execution risk increases as business scales on M&A: We believe that unlike the tuck-in acquisitions PSYS has successfully handled in the past, Nagarro is much larger (~23x Data Glove, which we believe was the largest acquisition by revenue thus far) and harder to execute especially as it pertains to Europe where laws are not as business friendly as in the US. We also see big revenue deflation risk due to Nagarro's T&M heavy revenue (68%). We also think that cross sell may not be as effective as it may seem on paper as we believe most of Nagarro's horizontal skills are 'retro'. PSYS's AI platform skill (SASVA) is the only big differentiator. Our concerns are captured in our post transaction note ([Big Deal, Bigger Risks](#))

Valuation: We have raised our EPS estimates for FY27-FY29 by 2-6% largely on expectation of better margins. We maintain the Target PE at 16.9x (20% premium to benchmark) and the stock rating continues to be SELL. At 34x, 12m forward multiple believe the current valuation is excessive and the street is being over optimistic about its earnings prospects in the long term.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	PSYS IN/Rs 5,575
Market cap	US\$ 9.2bn
Free float	69%
3M ADV	US\$ 41.0mn
52wk high/low	Rs 6,599/Rs 4,245
Promoter/FPI/DII	30%/21%/30%


Source: NSE | Price as of 3 Aug 2026

Key financials

Y/E 31 Mar	FY26A	FY27E	FY28E
Total revenue (Rs mn)	147,485	211,987	324,442
EBITDA (Rs mn)	27,955	38,208	56,492
Adj. net profit (Rs mn)	19,542	24,358	29,096
Adj. EPS (Rs)	118.9	153.9	183.8
Consensus EPS (Rs)	118.9	147.1	175.4
Adj. ROAE (%)	27.6	28.5	28.9
Adj. P/E (x)	46.9	36.2	30.3
EV/EBITDA (x)	31.6	21.2	13.1
Adj. EPS growth (%)	31.8	29.5	19.4

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



SELL**TP: Rs 2,869 | ▼ 8%****ESCORTS KUBOTA**

Automobiles

04 August 2026

Steady show; exports below par, no respite; retain SELL

- Steady growth in key markets North (22%) and Central (~15%) drives domestic volume up ~23% leading to ~36bps market share gain
- Gross margins compress ~358bps YoY due to cost inflation impacts of ~500bps; further ~1.5-2% cost impact expected in Q2FY27
- Retain FY27E/FY28E/FY29E EBITDA/EPS to factor growth offsetting cost Value at 20x P/E multiple; revise TP to Rs 2,869 (Rs 2,786). **SELL**

Milind Raginwar
 Research Analyst
Ayush Dugar
 Research Associate
 research@bobcaps.in

Volume steady aide marginal market share gains: ESCORTS Q1 revenue grew at 28.3%/8.1% YoY/QoQ to ~Rs32.1bn, driven by healthy tractor volumes growth of 20.5% YoY to ~36.9k units. Domestic tractor volumes grew 22.9% YoY, ahead of industry growth of 18.6%, resulting in a ~36bps market share gain, aided by stronger traction in North & Central markets, product refreshes and better channel execution. However, export volumes fell sharply to ~19% YoY (against industry growth) due to transportation issues and weak demand in the sub-40HP segment.

Margin under pressure despite operating leverage: RM costs surged ~35% YoY amid commodity inflation (~400bps) and minimum wage revision (~100bps). Gross margin effectively fell sharply to ~27.3% (vs ~30.9% YoY), although lower other expenses reflected ongoing cost-control initiatives. EBITDA increased ~10.3% YoY to ~Rs3.5bn, while EBITDA margin contracted ~180bps YoY to ~11.1%. ESCORTS indicated commodity inflation to remain elevated with an additional ~1.5-2% cost pressure expected in Q2FY27, while further price hikes are under evaluation.

Product launches to support growth: ESCORTS has planned launches across Farmtrac, Powertrac and Kubota brands, with new 4WD products planned in the medium term. Growth outlook was revised upward to mid-single digit growth and ESCORTS expects to outpace the industry through market share gains, supported by new products, expanding dealer network and captive financing penetration.

Maintain SELL: Intense competition, adverse regional mix, and commodity cost inflation are challenges in FY27 apart from a higher base effect. ESCORTS has also faced challenges selling Kubota tractors given the engine manufacturing woes. The exports growth is lagging far behind the industry growth. CE business revival will be handy. Effectively we retain our EBITDA/EPS for FY27E/FY28E/FY29E to domestic growth though margins will be under pressure. The new capacity benefits will be from FY29. Our 3-year EBITDA/PAT CAGR stays at 12%/8%. Limited presence in key regions like south India, cost pressure, weak exports will keep ESCORTS performance under pressure. We retain **SELL**. We revise our TP to Rs 2,869 (Rs 2,786) on rollover to Jun-2028 valuing at 20x stock's LT mean.

Key changes

Target	Rating
▲	◀ ▶


Ticker/Price	ESCORTS IN/Rs 3,136
Market cap	US\$ 4.4bn
Free float	63%
3M ADV	US\$ 5.0mn
52wk high/low	Rs 4,180/Rs 2,700
Promoter/FPI/DII	37%/22%/8%

Source: NSE | Price as of 3 Aug 2026

Key financials

Y/E 31 Mar	FY26P	FY27E	FY28E
Total revenue (Rs mn)	1,15,403	1,29,550	1,52,127
EBITDA (Rs mn)	14,963	15,304	18,403
Adj. net profit (Rs mn)	13,429	13,567	15,247
Adj. EPS (Rs)	120.0	121.3	136.3
Consensus EPS (Rs)	120.0	124.1	140.9
Adj. ROAE (%)	10.9	10.4	10.5
Adj. P/E (x)	26.1	25.9	23.0
EV/EBITDA (x)	28.1	27.1	22.6
Adj. EPS growth (%)	19.2	1.0	12.4

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance

Source: NSE



AUTOMOBILES

04 August 2026

Monsoon recovery not a dampener, July surprises positively

- OEMs continue positive volume growth momentum despite monsoon, entry level spurt boost PVs (37%); Premium segment spurts 2W (29%)
- Infrastructure spending and freight activity levels remain healthy as utilization sustains driving CV growth (~33% YoY)
- Improving monsoon and faster Kharif sowing sustain rural demand, supporting tractor growth (~20% YoY); 3W growth persistent (31% YoY)

Milind Raginwar
 Research Analyst
research@bobcaps.in

PVs pace in fast lane Passenger Vehicles (PV) marked July with strong growth as volumes across our coverage universe spiked ~37% YoY. MSIL grew by a strong ~42% YoY domestic growth, aided by small-car revival and healthy SUV demand. TMPV was the top gainer with 58% growth YoY helped by Punch face-lift in Q4FY26 and New Sierra launch in Q3FY26. MM's healthy SUV-led momentum continued with ~20% YoY growth and HMIL rebounded with ~25% YoY domestic growth as production normalized after supplier related issues in earlier month.

2Ws continue broad-based growth: 2W demand remained healthy, supported by strong domestic recovery and resilient exports. TVSL (~38% YoY) continued to outperform with strength across motorcycles, scooters and EVs. BJAUT (~31% YoY) sustained export-led growth (~42% 2W exports), HMCL (~19% YoY) witnessed healthy recovery across commuter motorcycles and scooters. EIM (~34% YoY) maintained robust momentum, supported by its core 350cc platform while >350cc shows recovery.

3Ws remain key mobility beneficiary: Passenger carrier demand and exports continued supporting the segment. MM/TVSL grew ~53%/~51% YoY, led by strong EV penetration and urban mobility demand. BJAUT (~23% YoY) also delivered healthy growth, with both domestic and export businesses contributing to volumes.

Tractors supported by improving monsoon: Tractor demand showed no signs of slowing down, supported by improved rainfall, stronger Kharif sowing and resilient rural sentiment. MM/ESCORTS domestic tractor sales grew ~20%/~22% YoY, aided by healthy wholesale and retail demand. VSTT remained weak (-9% YoY) as declining power tiller volumes more than offset stable mechanisation demand.

CV momentum remains robust: CV demand stayed strong, assisted by healthy freight movement, infrastructure activity and replacement demand. AL (~30% YoY) and VECV (~16% YoY) reported healthy growth led by trucks and LCVs, while TMCV (~38% YoY) sustained double-digit momentum, reflecting continued strength in the overall CV cycle.

Key ratings: Retain BUY on MSIL and MM; assign HOLD rating to the 2Ws pack (TVSL, EIM, BJAUT, HMCL) on fair valuations. SELL on VSTT.



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
 Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
 SEBI Research Analyst Registration No: **INH000000040 (Perpetual)**
 SEBI Stock Broker Registration No: **INZ000159332**
 SEBI Depository Participant Registration No: **IN-DP-728-2022**
 SEBI Merchant Banker Registration No: **INM000009926**
 Phone: +91-22-61389300
 Name of the Compliance Officer: Mr. Sameer Khobrekar
 Email ID: Compliance@bobcaps.in; Phone no.: +91-22-61389358
 For any queries or grievances, you may contact the Grievance Officer.
 Name of the Grievance Officer: Mr. Nilesh Mehta
 Email ID: head-customer@bobcaps.in; Phone no: 92288 60945

Brand Name: **BOBCAPS**
 Website: <https://www.bobcaps.in/>
 CIN: **U65999MH1996GOI098009**

Logo:  **BOBCAPS**
 TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
 Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.